BRAF and non-small cell lung carcinoma: According to the results of the systematic review, 45 (1.13%) NSCLC patients (all LUAD) had a BRAF class 1 alteration, 48 (1.21%) patients (of whom 45 LUAD) had a class 2 alteration, and 46 (1.15%) patients (of whom 43 LUAD) had a class 3 mutation (Figure 1B,C).